|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Northwestern University Feinberg School of Medicine, Department of Urology
Gary Schiltz (PI)*
Weinberg College of Arts and Sciences, Department of Chemistry
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 4/7/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
New Therapeutic Approach for the Treatment of Acute Myeloid Leukemia
NU 2017-214
Inventors
Ali Shilatifard*
Zibo Zhao
Short Description
A new therapeutic approach for the treatment of acute myeloid leukemia using casein kinase inhibitors.
Background
Leukemia is a group of cancers that affects the bone marrow and results in the overproduction of dysfunctional white blood cells (WBCs). The mixed lineage leukemia...
Published: 3/31/2026
|
Updated: 11/18/2025
|
Inventor(s):
Keywords(s): Cancer/Oncology, Leukemia, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Small Molecule Inhibitors of BAP1 for Cancer Therapy
NU 2019-130
PRIMARY INVENTOR
Ali Shilatifard
SHORT DESCRIPTION
A series of small molecule compounds targeting the BAP1 complex for the treatment of leukemia.
BACKGROUND
ASXL1, which encodes a core component of the BAP1 histone H2A deubiquitinase complex, is one of the most frequently mutated genes in malignant myeloid diseases. Mutations of ASXL1...
Published: 3/31/2026
|
Updated: 2/15/2022
|
Inventor(s):
Keywords(s): Biomedical, Cancer/Oncology, Leukemia, Small molecule
Category(s): Life Sciences > Therapeutics
|